




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 9/14	A1	(11) International Publication Number: WO 92/06678 (43) International Publication Date: 30 April 1992 (30.04.92)
(21) International Application Number: PCT/US91/07051		(74) Agents: SCHNEIDER, Carol, A. et al.; 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US).
(22) International Filing Date: 25 September 1991 (25.09.91)		
(30) Priority data: 598,880 15 October 1990 (15.10.90) US		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent).
(71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West Seventh Street, Austin, TX 78701 (US).		
(72) Inventors: HUBBELL, Jeffrey, A. ; 3006 Beverly Road, Austin, TX 78741 (US). SAWHNEY, Amarpreet, S. ; 1910 Willow Creek, #206, Austin, TX 78741 (US).		Published <i>With international search report.</i>

(54) Title: BIOCOMPATIBLE MICROCAPSULES



(57) Abstract

Biocompatible microcapsules useful for transplanting foreign material into an animal body, and the method of their production, are described, wherein the microcapsules contain an outermost layer of water soluble non-ionic polymers such as PEO to create resistance to cell adhesion on the surface of the microcapsules.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BC	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

DESCRIPTIONBiocompatible MicrocapsulesBackground

Microencapsulation of materials for transport to and/or growth within an animal is an area of research currently attracting much interest. The use of 5 microcapsules provides the potential for such medically important procedures as treatment of insulin-dependent diabetes mellitus (IDDM) in humans through transplantation of insulin-producing cells, and timed release or long term delivery of drugs to an animal.

10 The microencapsulation membrane plays a critical role in the treatment of IDDM by microencapsulated islet cells, as well as treatment of other diseases with other encapsulated material. Not only must it prohibit proteins of the immune system from entering the capsule, but it 15 must also interact with the host tissues in a biocompatible way. In this sense, biocompatibility means that the membrane will not initiate an inflammatory response and that it will not support cell adhesion and stimulate overgrowth. If overgrowth occurs, the oxygen 20 and nutrient supply to the islets will be limited and they will die. The area of biocompatibility of microcapsules, however, has received relatively little attention.

The principle of immunoisolation is to surround the cells with a biocompatible semipermeable membrane, which 25 allows free diffusion of nutrients, messenger compounds, cell wastes, and cell products, while isolating the cells from the host's immune system. The cells may be individual or clumped in tissue. Messenger compounds and cell products include glucose, Ca^{2+} , and insulin.

30 Two methods for the immunoisolation of cells exists: hollow-fiber devices and microencapsulation. One form of hollow-fiber devices are an artificial capillary system consisting of hollow fiber to which cells are seeded on

their exteriors, and which are enclosed in a rigid chamber that is connected to the recipient as a vascular shunt. Early devices using insulin producing cells reversed diabetes for limited periods with high doses of heparin.

5 Sun et al. (1977) *Diabetes*, 26:1136-39. But even with heparin, blood clot formation was a major problem. To reduce the formation of clots, which suffocated the cells, Altman et al. have seeded Amicon fibers successfully, with nearly half of the animal recipients having normal blood

10 glucose levels for over a year. Altman et al. (1986) *Diabetes*, 35:625-33. However, the Amicon fibers are fragile and they have a limited surface area available for diffusion. A U-shaped ultrafiltration design developed by Reach et al. can solve the diffusion problem, but this

15 design still suffers from the fragility of the Amicon fibers and from the formation of blood clots at the junction with the vascular system. Reach et al. (1984) *Diabetes*, 33:752-61.

The transplantation of microencapsulated cells or tissue can overcome the hollow-fiber associated problems of diffusion limitations and vascular complications. Originally, Sun and Lim demonstrated the technique by encapsulating rat pancreatic islet cells into a membrane composed of layers of alginate, polylysine, and

25 polyethyleneimine. Sun and Lim (1980) *Science*, 210:908-910. The microcapsules were injected into chemically induced diabetic rats. These microcapsules corrected the diabetic state for only 2 to 3 weeks.

Gradually the technique improved. A large improvement was making the multi-layer membrane from alginate-polylysine-alginate, which is stronger and has controllable permeability parameters. Goosen et al. (1985) *Biotech. and Bioengin.*, XXVII:146-50. King and Goosen et al. developed methods for decreasing the viscosity of the gel inside so that the tissue or cells are in a more natural environment (1987) *Biotechnology Progress*, 3:231-240. A further advance was making the

microcapsules in a more uniform, smooth, spherical shape which improved their strength. Walter et al. Poster Group H.

With these changes, Sun et al. have transplanted rat 5 islets of Langerhans into chemically induced diabetic rats which have reversed the diabetic state for up to 780 days, Sun (1987) Trans Am Soc. Artif. Intern Organs, XXXIII:787-790. In vitro studies have shown that antibodies from Type 1 human diabetic patients were not able to suppress 10 encapsulated cells, Darquy and Reach (1985) Diabetologia, 28:776-80. Therefore, it seems that microencapsulation can protect cells from antibodies. However, there are still several serious problems in regards to biocompatibility. Sun has reported finding fibroblast- 15 like cells on the external surfaces of intact microcapsules. Sun had transplanted the microencapsulated rat islet cells into diabetic rats. Sun (1987) Trans Am. Soc. Artif. Intern Organs XXXIII:787-790. In his articles, Sun has specifically recognized the need to 20 improve the biocompatibility of the microcapsules. Id. at 810.

Other published studies have also seen this inflammatory response to transplanted microencapsulated cells. In another study of microencapsulated rat islet 25 cells, O'Shea and Sun found that the microcapsules that they transplanted into chemically induced diabetic mice had cell overgrowth in the range of 0-10 layers of cells. The overgrowing cells included fibroblasts, macrophage-like cells and neutrophils. There was also collagen 30 around the capsules. O'Shea and Sun (1986) Diabetes, 35:943-946. Again, O'Shea and Sun expressly recognized that the bio-compatibility of the microcapsules must be improved. Id. at 946.

The inflammatory response is not limited to 35 transplants of islet cells. Wong and Chang have reported recovering clumped microcapsules of rat hepatocytes after they were transplanted into mice with liver failure. They

found no viable cells within the clumped microcapsules, which were recovered only seven days after transplantation. Wong and Chang (1988) Biomat., Art. Cells, Art. Org., 16(4):731-739. The cells probably died because they were cut off from nutrients when the cells grew over the semi-permeable membrane.

Current formulations for microcapsules result in algin--polycationic polymer--algin composites. The exterior of these membranes are negatively charged, due to the algin, and may have positive charges due to exposed polycation; as such they support protein adsorption and cell attachment. In general, these microcapsules become overgrown with fibroblasts and other cells. This overgrowth has many negative effects, including impairment of the functioning of the microcapsule by blocking permeability, and induction of immune response by the host animal.

The microencapsulation technique that had previously met with the most success is that of O'Shea and Sun (1986) Diabetes, 35:943-946. Their method uses the strong interaction between large multicharged molecules, one cationic and one anionic, to form a very thin, stable, spherical membrane shell that resists the diffusion of large proteins, such as antibodies, while allowing the diffusion of smaller proteins, such as insulin.

Such a membrane is obtained by suspending cells to be encapsulated in a solution of algin, a polyanionic polysaccharide that is obtained from kelp. Very small droplets of this solution are formed, approximately 0.1-1.0 mm in diameter depending on the size of the material to be encapsulated, and these droplets are gelled on contact with a fairly highly concentrated solution of calcium chloride, 0.2-1.6% CaCl₂. The calcium cations, in this high concentration, serve to reversibly crosslink the anionic polysaccharide chains, forming the gel.

To obtain a membrane that would be stable at physiologic concentrations of calcium, the negatively

charged microcapsule is placed in a solution of a positively charged polymer, for example, polylysine. The opposite charges interact, leading to very strong adsorption of the polylysine, resulting in a stable, 5 strongly crosslinked surface. Similarly, an outer layer of algin is added, yielding an algin-polylysine-algin composite trilayer membrane.

The solid inner core of gelled algin is liquefied by placing the microcapsules in a solution of sodium citrate 10 to chelate the gelling calcium. At physiologic calcium levels, the core remains liquid and the algin, if of low enough molecular weight, diffuses out of the core. The result is a spherical shell of algin-polylysine-algin surrounding the microencapsulated cells.

15 It is predictable that such an algin-polylysine-algin microcapsule will not resist tissue overgrowth. The exterior surface is highly charged, with both positive and negative charges, and would thus be expected to adsorb significant amounts of protein and to support cell adhesion. Andrade et al. (1986) *Adv. Polymer Sci.*, 79:1-63. Experimentally, tissue overgrowth has been observed to be the point of failure of the microencapsulation therapy. O'Shea and Sun (1986).

Poly(ethyleneoxide) (PEO) has been used in numerous 25 instances to decrease cellular attachment. For instance, PEO coatings on PVC tubes have been reported as significantly reducing platelet adhesion in vitro and preventing adhesion and thrombus formation in 72 day PVC tube implants in vivo. (Y. Mori et. al., *Trans. Am. Soc. 30 Artif. Intern. Organs* 28:459 (1982)). Volume restriction and osmotic repulsion effects were credited with producing the low adsorption of blood constituents. (Id.). Later research concluded that there were micro flows of water induced by the cilia-like movements of hydrated PEO chains 35 which prevent plasma proteins from absorbing onto the surface of coated PVC tubes. (S. Nagaoka and A. Nakao, *Biomaterials* 11:119 (1990)).

In addition to PVC tube coatings, others have reported that segmented polyurethanes containing PEO as the soft segment, when cast as films or coatings, show reduced platelet retention in vitro. (E.W. Merrill *et al.*, Trans. Am. Soc. Artif. Intern. Organs 28:482 (1982)). PEG-polyurethane coatings on disks made of Pellethane were shown to cause the disks to have reduced cellular adhesion for up to 3 months when implanted into the peritoneal cavities of mice. (S.K. Hunter *et al.*, Trans. Am. Soc. Artif. Intern. Organs 29:250 (1983)). Block co-polymers consisting of poly(N-acetylethyleneimine) and PEO, when coated on solids such as glass beads or silica, were found to increase the homeo-compatibility of the solids by decreasing adsorption of hydrophilic macromolecules. (C. Maechling-Strasser *et al.*, J. of Biomedical Materials Research 23:1385 (1989)).

Long term canine vascular implants of Biomer coated with polymers have been tested for adsorption of proteins. (C. Nojiri *et al.* Trans. Am. So. Artif. Intern. Organs, 35:357 (1989)). The polymer coatings found to have "excellent non-thrombogenic performance" were: 1) Heparin immobilized on Biomer using a long chain PEO spacer; and 2) a block copolymer composed of 2-hydroxyethyl methacrylate (HEMA) and styrene. (*Id.*).

Low density polyethylene (a hydrophobic polymer surface) coated with a block copolymer containing water insoluble components (such as polypropylene oxide or polybutylene oxide) and PEO components (water soluble components) was shown to have protein resistant properties. (J.H. Lee *et al.*, J. of Biomedical Materials Research, 23:351 (1989)). The surface was created by a simple coating process where the hydrophobic components of the polymer adsorbed on the hydrophobic surface of the polyethylene from an aqueous solution, the PEO chains were then at least partially extended into the aqueous solution creating a protein resistant surface. (*Id.*).

Processes used to achieve PEO surfaces other than a simple coating process have been described: block copolymerization (Y. Mori *supra*); incorporation into polyurethanes (E.W. Merrill *supra*); and direct attachment 5 of PEO molecules to the cyanuric chloride activated surface of a poly(ethylene terephthalate) film. (W.R. Gombotz *et al.*, J. of Applied Polymer Science 37:91 (1989)).

Most of the foregoing uses of PEO have been on 10 concave or flat surfaces; they have not been on small convex surfaces such as are found with microcapsules. Due to the fact that the non-ionic water soluble polymers face outward from the microcapsule, it could not be predicted from the prior art that PEO and other non-ionic water 15 soluble polymers could form a sufficient barrier to protect microcapsular surfaces. Likewise, the chemistry was not known for attaching sufficient quantities of water soluble non-ionic polymers to the outer surfaces of microcapsules to create this barrier.

20 Summary of the Invention

This invention for the first time demonstrates the use of water soluble non-ionic polymers such as PEO to create resistance to cell adhesion on the surface of microcapsules.

25 This invention provides a method for transplanting foreign material into an animal body in a biocompatible manner. This is accomplished by providing microcapsules, biocompatible with the recipient animal, capable of encapsulating the foreign material to be transplanted into 30 that animal. The normally charged outer layer of the microcapsules is covered by water soluble non-ionic polymers such as poly(ethylene oxide) (PEO) which act to shield the charge. These polymers are grafted to the polycationic polymers, such as poly-L-lysine (PLL) 35 molecules used as at least one of the layers of the microcapsule, such that they create a non-ionic barrier

- between the outer layer of the microcapsule (made of essentially either polycationic polymers, such as PLL, or polyanionic polymers, such as alginate) and the recipient animal. The microcapsules then appear, from the outside,
- 5 to have water-like surface properties, thus reducing the driving force for protein adsorption. Further, the surface, at the macromolecular level, is in a high degree of motion, further reducing protein adsorption and cell attachment.
- 10 This invention further provides microcapsules, and a method for their production, in which the surface is more resistant to cell adhesion. As a result, overgrowth of the microcapsules by cells such as fibroblasts and macrophages is severely decreased or eliminated. Cells
- 15 contained within the microcapsules are able to continue to receive nutrients and signal molecules, and produce whatever is their desired product. Any product present in the microcapsules, such as insulin produced by islet cells, can continue to diffuse out of the microcapsules
- 20 and be available for utilization by the host animal.

This invention also provides microcapsules, and a method for their production, which will not appreciably stimulate immune response or cytokine release by the recipient animal. Thus, these microcapsules can be

25 transplanted to a recipient animal and function there with minimal interference from that animal's immune system.

This invention provides microcapsules with variable levels of permeability. This is accomplished by using varying numbers of layers to make the microcapsules, with

30 an increased number of layers decreasing the pore size. Thus, the microcapsules can be created to meet a particular need for large or small pores and the resulting level of permeability.

Figures

Figure 1 shows the effect of the molecular weight of the water soluble non-ionic polymer on permeability of microspheres formed using grafted material.

5 Figure 2 shows the effect of the number of layers used to form the microspheres on permeability.

Figure 3 is a schematic of the activation reaction using carbodiimidazole.

10 Figure 4 is a schematic of the activation reaction using sulfonyl chlorides, where R is as shown.

Figure 5 is a schematic of the activation reaction using chlorocarbonates.

15 Figure 6 shows cell counts obtained from peritoneal lavage after implantation of microcapsules. CDI (carbodiimidazole), PFBS (pentafluorobenzenesulfonyl chloride), trifyl (trifyl chloride), and chlorocarb (chlorocarbonate) were used to activate PEO (poly(ethylene oxide)) for grafting to poly(l-lysine) according to this invention. Figure 6a represents results when PEO of 20 molecular weight around 5kd was used; figure 6b used PEO of 10kd; and Figure 6c shows results from PEO of 18.5kd. Numbers of cells are shown on the left of each graft. e+7 stands for 10^7 , so that 1.00e+7 is 1.00×10^7 cells.

25 Figure 7 shows growth of cells on microspheres made by the standard procedures available prior to this invention, using ungrafted poly(l-lysine). Figure 7a is 40X phase contrast magnification of microspheres, while figure 7b is 400X.

30 Figure 8 shows microspheres made with poly(ethylene oxide) (PEO) activated by carbodiimidazole and grafted to poly(l-lysine) (PLL) to create PEO-g-PLL. In figure 8a 5 kd PEO was used; in figure 8b the PEO was 10 kd, and in figure 8c the PEO was 18.5 kd. These figures show the whole microspheres magnified 40X.

35 Figure 9 shows microspheres made with PEO activated by trifyl chloride and grafted to PLL to create PEO-g-PLL. In figures 9a and 9b, 5 kd PEO was used. In figures

9c and 9d, the PEO was 10 kd, and in figures 9e and 9f the PEO was 18.5 kd. Figures 9a, 9c and 9e show whole microspheres, photographed at 40X, while figures 9b, 9d and 9f show 400X magnified surfaces of the microspheres.

5 Figure 10 shows microspheres made with PEO activated by pentafluorobenzenesulfonyl chloride (PFBS) and grafted to PLL to create PEO-g-PLL. In figure 10a 5 kd PEO was used; in figure 10b the PEO was 10 kd, and in figure 10c the PEO was 18.5 kd. These figures show the whole
10 microspheres magnified 40X.

Figure 11 shows microspheres made with PEO activated by chlorocarbonate and grafted to PLL to create PEO-g-PLL. In figures 11a and 11b, 5 kd PEO was used. In figures 11c and 11d, the PEO was 10 kd, and in figures 11e
15 and 11f the PEO was 18.5 kd. Figures 11a, 11c and 11e show whole microspheres magnified 40X, while figures 11b,
11d and 11f show surfaces of the microspheres magnified
400X.

Detailed Description

20 According to this invention, microcapsules are assembled from various layers of a polyanionic polysaccharide, such as alginate, and a polycationic polymer, such as poly(l-lysine) (PLL). The polycationic polymer need not be a polypeptide. The outer polycation
25 layer is composed of the polycationic polymer grafted to a water soluble non-ionic polymer, such as poly(ethylene oxide) (PEO) to form a graft copolymer, such as PLL-g-PEO. The layers are alternated such that the oppositely charged polymers, for example algin and PLL, aggregate to
30 form coacervates, such as algin--PLL--algin. This creates an ionically crosslinked membrane.

However, PLL is known to promote cell adhesion, so at least the outermost layer of PLL or other polycation in this invention is composed of the graft copolymer. PEO,
35 as well as other water soluble non-ionic polymers, have been shown to reduce cell adhesion when used to modify a

surface. Lee et al. (1989) J. Biomed. Materials Res. 23:351-368. This dual-character graft copolymer interacts with the polyanionic layer, such as algin, to form a stable membrane through interactions between the 5 polycationic backbone, such as PLL, and the polyanionic layer. The long arms of the non-ionic polymer, such as PEO, however, serve to obscure the charged layers from the tissues, thereby improving the biocompatibility. They create a very hydrophilic and uncharged layer, to which 10 very little, if any, protein or cells adhere.

The water soluble non-ionic polymers are covalently attached to the polycationic polymers and point in all directions including outward from the microcapsule.

1. Water Soluble Non-ionic Polymers

15 Water soluble non-ionic polymers with molecular weights of between 2000 and 50,000 are suitable for this procedure. PEO of approximately 10,000 m.w. is the most preferred. Molecules with molecular weights lower than around 2000 do not adequately shield the microcapsule, 20 while those greater than around 50,000 create stearic limitations on the microcapsules. In addition, molecules with higher molecular weights cause an increase in the swelling of the microcapsules, interfering with the interactions between the polyanionic polysaccharides and 25 the polycationic polypeptides. As a result, the polyanionic polysaccharide layer does not adhere as well, and the integrity of the microcapsules can be threatened.

Additionally, the size of the water soluble non-ionic polymers affects permeability of the microcapsule. 30 The larger molecules create greater permeability. This feature can be manipulated to obtain the optimal degree of permeability for the particular use of the microcapsules. For microcapsules encapsulating insulin-producing islet cells, the optimal permeability is created with PEO around 35 10,000 m.w. in a pentalayer membrane (see below and figures 1 and 2).

2. Activation

Procedures used to graft the water soluble non-ionic polymers to the polycationic polymers include but are not limited to use of carbodiimidazole, sulfonyl chlorides, or 5 chlorocarbonates to activate the water soluble non-ionic polymers. These reagents are used to activate free hydroxyl groups for coupling to polycationic polypeptides.

Other chemistries for linking water soluble non-ionic polymers to polycationic polymers, known by those 10 skilled in the art, can also be used.

a. Carbodiimidazole

To X millimoles of PEO or other water soluble nonionic polymer in at least a 1% solution in anhydrous acetone or other anhydrous organic solvent is added at 15 least 1X, preferably 5X millimoles of carbodiimidazole. Larger quantities of carbodiimidazole can be used but will not increase the rate or amount of the activation. The reaction mixture is stirred at a temperature above the freezing point and below the melting point of the mixture, 20 preferably at room temperature of around 22°C, for at least ½ hour, preferably around 2 hours. The product is then washed at least twice with methanol with HCl or other strong acid to convert the organic base to the conjugate, and finally with pure methanol. Washes can be formed by 25 solubilization of the reaction product in the wash solvent, followed by reprecipitation and sedimentation, for example by settling at 1g or in a centrifuge at higher acceleration, preferably 1000 rcf for 10 minutes. The final wash is checked to be free of any residual pyridine 30 or other base by UV spectrophotometry. The pelleted product is then recovered. Other purification schemes known by those skilled in the art can also be used. The product can then be lyophilized and stored. Figure 1 shows the reaction scheme.

b. Sulfonyl chlorides

To create good leaving group characteristics in sulfonyl chlorides, two main approaches are used: the first is fluorination and the second is nitration. Thus 5 a number of organic chlorides can be used to produce end-activated water soluble non-ionic polymer chains with a varying degree of effectiveness. By way of example, the order of reactivity of coupling for Toluene sulfonyl chloride (Tosyl chloride) : Trifluoroethanesulfonyl 10 chloride (Tresyl chloride) : Trifluoromethanesulfonyl chloride (Trifyl chloride) is 1:100:4000. As reactivity increases, stability decreases. Therefore an organic chloride with intermediate traits is preferred. Other sulfonyl chlorides such as dansyl, dipsyl, and diabsyl 15 chloride can also be used, but with lower effectiveness. Other problems such as difficulty in removal of unreacted dansyl functions by nucleophiles and tendency for diabsyl chloride to undergo further secondary reactions leading to a significant red shift make these sulfonyl chlorides less 20 suitable. These may be overcome, for example, by employing higher levels of the activating agent and subsequently purifying the products of the primary reaction from the products of the secondary competing reactions.

25 Another compound, Pentafluorobenzenesulfonyl chloride (PFBS), however, is as reactive as tresyl chloride, is cheaper, and is chromophoric, thus allowing an easy quantification of the extent of the reaction. Thus PFBS is a preferred reagent in this group.

30 Sulfonyl chlorides are readily available from a number of commercial chemical suppliers such as Aldrich and Fluka.

To X millimoles of PEO or other nonionic water soluble polymer in at least a 1% solution in anhydrous 35 methylene chloride or other anhydrous organic solvent at a temperature above the freezing point and below the melting point of the mixture, preferably 4°C, is added at

least 1X, preferably 5X millimoles of sulfonyl chloride (larger quantities can be used but will not increase the rate or amount of the activation) and approximately twice as much pyridine, triethylamine, or other organic aphotic 5 base, as sulfonyl chloride. The reaction mixture is stirred for at least 10 minutes, preferably around 2 hours. The product is then washed at least twice with methanol with HCl or other strong acid to convert the organic base to the conjugate, and finally with pure 10 methanol. Washes can be formed by solubilization of the reaction product in the wash solvent, followed by reprecipitation and sedimentation, for example by settling at 1g or in a centrifuge at higher acceleration, preferably 1000 rcf for 10 minutes. The final wash is 15 checked to be free of any residual pyridine or other base by UV spectrophotometry. The pelleted product is then recovered. Other purification schemes known by those skilled in the art can also be used. The product can then be lyophilized and stored. Figure 2 shows the reaction 20 scheme.

c. Chlorocarbonates

Chlorocarbonates such as P-nitrophenyl chlorocarbonate (Fluka), 2,4,5 trichlorophenyl chlorocarbonate, and N-hydroxysuccinamide chlorocarbonate 25 are examples that react efficiently for activation of hydroxyl containing compounds such as the water soluble non-ionic polymers used in this invention. Other chlorocarbonates known by those skilled in the art can also be used.

To X millimoles of PEO or other water soluble nonionic polymer in at least a 1% solution in anhydrous methylene chloride or other anhydrous organic solvent at a temperature above the freezing point and below the melting point of the mixture, preferably 4°C, is added at 30 least 1X, preferably 5X millimoles of chlorocarbonate 35 (larger quantities can be used but will not increase the

rate or amount of the activation) and approximately twice as much pyridine, triethyl amine or other organic aphotic base. The reaction mixture is stirred at a temperature above the freezing point and below the melting point of 5 the mixture, preferably at room temperature of around 22°C, for at least 10 minutes, preferably around 2 hours. The product is then washed at least twice with methanol with HCl or other strong acid to convert the organic base to the conjugate, and finally with pure methanol. Washes 10 can be performed by solubilization of the reaction product in the wash solvent, followed by reprecipitation and sedimentation, for example by settling at 1g or in a centrifuge at higher acceleration, preferably 1000 rcf for 10 minutes. The final wash is checked to be free of any 15 residual pyridine or other base by UV spectrophotometry. The pelleted product is then recovered. Other purification schemes known by those skilled in the art can also be used. The product can then be lyophilized and stored. Figure 3 shows the reaction schemes.

20 3. Polycationic Polymers

Polycationic polymers are selected for their ability to form strong membrane coacervates with algin or other polyanions. Such polycationic polymers include polypeptides and non-polypeptides. Polypeptides include, 25 but are not limited to, polylysine and polyornithine. Non-polypeptides include, but are not limited to, polyethyleneimine and polyallylamine. The molecular weight of these polycationic polymers is important but not critical, and optimal values are determined by their 30 ability to form strong membrane coacervates. Very low molecular weight polycation polymers generally form membranes that are weak and very high polycation polymers generally form membrane coacervates that are very thin. Typical values for the molecular weight of the polycation 35 polymers are between about 10,000 and 75,000. A preferred substrate is poly(l-lysine), which has been previously

used in its ungrafted form as a component of microcapsule membranes.

4. Coupling

Activated water soluble non-ionic polymers are next coupled to the polycationic polymers. The polymers are mixed into a solution of the activated PEO or other water soluble nonionic polymer, agitated and allowed to react for a period of at least 1/2 day. The pH of the solution is maintained around 9±2. The coupling reaction is stopped by quenching through the addition of an amine or a thiol such as mercaptoethanol. Quenching is allowed to proceed for at least 1/2 hour, preferably 10 hours.

If desired, ultrafiltration, dialysis, or Soxlet extraction can be used to separate the unreacted PEO from the PLL-g-PEO. In addition, the extent of reaction can be estimated using a spectrophotometric titration of amine groups where, for example, the amine groups are reacted with 2,4,6-trinitrobenzene sulfonic acid, forming a product that absorbs at 440 nm. The extent of reaction can also be determined by estimating the relative amounts of copolymers using ¹H-NMR.

5. Formation of Microcapsules

Formation of the microcapsule is by standard techniques. O'Shea and Sun (1986). Material to be encapsulated is suspended in a solution of polyanionic polysaccharides, preferably algin, at a concentration that will allow the cells to receive adequate nutrients as well as signal molecules and produce the desired product(s) once the microcapsules are formed. A preferred concentration is 1 x 10⁵ to 1 x 10⁸ cells/ml. Droplets of this solution are dropped into a solution of isotonic calcium chloride in saline, preferably 0.2 to 1.6% CaCl₂ · 2H₂O. Passing the solution under pressure through a fine-gauge needle or orifice in a sterile air stream is one method of producing the droplets. They are then

washed in isotonic saline or buffer and placed in a solution of the polycationic polymer, preferably PLL. Alternatively, they can be placed in a solution of water soluble non-ionic polymer-grafted-polycationic polymer, as 5 described herein. The polycationic polymer or water soluble non-ionic polymer-grafted-polycationic polymer solution should be approximately 0.03%-0.3%, preferably 0.1%. The droplets are allowed to react with the polymers for a period of time from 3-30 minutes, preferably 12 10 minutes.

The microcapsules are removed from the polymer solution by, for example, decanting the liquid. The 2-layer droplets are then washed with isotonic saline or buffer and may be coated with one or more layer of 15 polyanionic polysaccharides, preferably another layer of algin. This is accomplished by reacting the bilayer droplets with a 0.05-0.25% solution of polyanionic polysaccharide, preferably a 0.15% solution of algin, for a period of 3-30 minutes, preferably 8 minutes.

20 Next, a layer of water soluble non-ionic polymer-grafted-polycationic polymer, preferably PEO-g-PLL, can be added to the microcapsule. This is performed by incubation of the microcapsules in a solution of the grafted polymer at the same concentration range, for the 25 same period of time, as for the non-grafted polycationic polymers. Alternatively, the first layer of polycationic polymer may be replaced by water soluble non-ionic polymer-grafted-polycationic polymer, such as PLL-g-PEO, and the second layer of this grafted-polycationic polymer 30 may be included or omitted. An outer layer of algin may or may not be added at the same concentration range, for the same period of time, as for the inner one.

35 The number of layers used in each microcapsule can be used to determine several parameters of interest for transplantation. The prior art discloses use of microcapsules with 3 layers, as described in O'Shea and Sun (1986). The number of layers can be increased by

adding subsequent alternating layers of polyanionic polysaccharides and polycationic polypeptides. The polycationic polymers grafted to the water soluble non-ionic polymers should at least be used as the last or 5 next to last layer of the microcapsule, and must be at least the outermost polycationic layer.

Increasing the number of layers decreases the permeability of the microcapsules. Thus, permeability can be controlled to selectively allow diffusion across the 10 microcapsule membrane. The addition of water soluble non-ionic polymers to the polycationic polypeptide layer increases permeability. Therefore, in order to eliminate the immune response of the host animal to cells encapsulated within these microcapsules, such as xenograft 15 insulin producing islet cells, it is necessary to counter this permeability increase. A preferred method is to add an additional two layers to the surface of the microcapsule. This brings the permeability back to the level found in 3-layer microcapsules described in the art 20 which do not have the grafted water soluble non-ionic polymers.

Additionally, increasing the number of layers of the microcapsule membrane increases the strength and stability of the microcapsules. However, this stability must be 25 balanced with the decrease in permeability caused by the increased layers. Thus, for use in encapsulating living cells that produce a desired product when transplanted to a host animal, a 5-layer microcapsule according to this invention is most preferred, whether made with both 30 ungrafted and grafted polycation polymer or solely with grafted polycation polymer.

Microcapsules formed by the above procedures can be degelled at this step to remove excess gelled polyanionic polysaccharide immediately surrounding the encapsulated 35 material. However, this procedure is not a necessary step, and the microcapsules will function well without degelling. If degelling is desired, standard procedures

described in the art, such as incubation in a sodium citrate solution can be employed. O'Shea and Sun (1986).

6. Implantation of Microcapsules

Microcapsules are suspended in a solution compatible
5 for injection, such as isotonic saline, buffer or tissue culture medium. Microcapsules can be implanted in the peritoneal cavity of a host animal by standard techniques. In addition, they can be implanted in any bodily location which provides sufficient circulation of the products of
10 the encapsulated material to allow metabolic functioning of those products. For example, with microcapsules containing insulin-producing islet cells, intramuscular locations will allow sufficient exposure to the blood circulatory system to allow effective use of the insulin.

15 Example 1

Activation of PEO Using Carbodiimidazole

Three separate reactions were performed, each using PEO of a different molecular weight class. 1 millimole each of PEO-5K (5000 d), PEO-10K (10,000 d) and PEO-18.5K (18,500 d) were used. The PEO-5K material was monomethoxy end terminated; as such these polymers had only one terminal, activatable hydroxyl group, thus minimizing cross-linking reactions in the coupling step. 50% solutions of these polymers were made up in anhydrous acetone which had been dried overnight over 4 Å molecular sieves, and 5 millimoles of carbodiimidazole (CDI) was added to them. The reaction mixes were stirred at room temperature for 2 hrs. The reaction mixes were then washed four times with 60 ml of anhydrous acetone by chilling the solution to 0°C to precipitate, decanting, adding fresh solvent, and warming to 22°C to redissolve. The product was then lyophilized and stored.

Example 2Activation of PEO Using Sulfonyl Chlorides

Three separate reactions were performed, each using PEO of a different molecular weight class. 1 millimole each of PEO-5K, PEO-10K AND PEO-18.5K were used. The PEO-5K material was monomethoxy end terminated; as such these polymers had only one terminal, activatable hydroxyl group, thus minimizing cross-linking reactions in the coupling step. 50% weight/volume solutions of these polymers were made up in anhydrous acetone which had been dried overnight over 4 Å molecular sieves. The solutions were cooled to 4°C and 5 millimoles of triflyl chloride or PFBS was added to these solutions along with 10 millimoles of pyridine. The reaction mix was stirred mechanically at room temperature for 2 hrs., at the end of which it was washed twice with 60 ml each of methanol containing 0.2 ml concentrated HCl, three times with 60 ml each of methanol containing 50 µl of HCl, and finally with pure methanol. The washes were done by solubilization at 40°C and precipitation at 4°C followed by centrifugation at 1000 rcf. The final wash was checked to be free of any residual pyridine by ultraviolet spectroscopy. The product was lyophilized and stored at 4°C.

Example 3Activation of PEO Using p-Nitrophenyl Chlorocarbonate

Three separate reactions were performed, each using PEO of a different molecular weight class. 1 millimole each of PEO-5K, PEO-10K AND PEO-18.5K were used. The PEO-5K material was monomethoxy end terminated; as such these polymers had only one terminal, activatable hydroxyl group, thus minimizing cross-linking reactions in the coupling step. 50% solutions of these polymers were made up in acetone which had been dried overnight over 4 Å molecular sieves. The solutions were then cooled to 4°C and 5 millimoles each of pyridine and triethylamine and 5 millimoles of p-nitrophenyl chlorocarbonate (chlorocarb)

were added. The mixtures were mechanically stirred and the reaction was allowed to proceed at room temperature for 2 hrs. The reaction mix was then washed with cold acetone by adding 60 ml acetone at room temperature, 5 cooling to 4°C and centrifuging at 1000 rcf. The washing was repeated once with acetone, then with a 5% acetic acid solution in dioxane, and finally with methanol. The product was lyophilized and stored.

Example 4

10 Coupling Activated PEO to PLL

20 mg of Poly(l-lysine) (PLL), molecular weight around 17,000, was added to each 50% w/v solution of the above activated polymers in 500 mM sodium borate buffer (pH 9) for 24 hours. The coupling reaction was stopped by 15 quenching using 0.36 mls of 14M Mercaptoethanol. The quenching was allowed to proceed for 10 hrs.

The PEO-5K grafted to PLL and PEO-10K grafted to PLL formed clear solutions. On the other hand, the PEO-16.5K grafted to PLL resulted in the formation of a very high 20 molecular weight macromolecular network which had the consistency of a gel. Some parts of this gel were soluble when diluted further but some crosslinked portions remained insoluble.

No attempt was made to separate the unreacted PEO 25 from the PLL-g-PEO. The extent of reaction was estimated using spectrophotometric titration of amine groups where the amine groups were reacted with 2,4,6-trinitrobenzene sulfonic acid, forming a product that absorbs at 440 nm.

Example 5

30 Relationship of Molecular Weight of the Water Soluble Non-Ionic

Polymer to Permeability of Microspheres

Use of grafted water soluble non-ionic polymer to polycationic polymer was found to affect the permeability 35 of microcapsules. Microspheres were formed using PEO of

varying molecular weights grafted to PLL as the outer layer of a bilayer microsphere. The relationship of the size of the PEO used to the permeability of the microspheres was investigated.

5 5 ml of algin solution was mixed with 100 μ l of ^{125}I labelled BSA for microsphere fabrication. Microspheres were formed following standard procedures. PLL-g-PEO having PEO chains of 5,000d, 10,000d, and 100,000d were used as the outer layer. Control spheres were formed
10 having ungrafted PLL as the outer layer. The microspheres were degelled with citrate. The degelled microspheres were incubated in 10 ml of citrate solution, which was sampled periodically for presence of ^{125}I albumin that had secreted through the membrane. For this sampling, 1 ml
15 aliquots were counted in a gamma scintillation counter. As can be seen in Figure 1, permeability of the microspheres increased in direct proportion to the size of the PEO component of the outer layer, with control spheres having ungrafted PLL being the least permeable.

20 The effects of the presence of PEO on permeability could be reversed by increasing the number of layers used to form the microspheres. Following standard procedures, microspheres were formed having from two to four layers. As can be seen in Figure 2, microcapsules with PEO having
25 4 layers, where the inner polycationic layer was of ungrafted PLL, had the same permeability characteristics as the control microcapsules with 3 layers. Thus, varying the number of layers altered the permeability characteristics of the microspheres, and increasing the
30 number of layers, using an inner layer of ungrafted PLL, returned the microcapsules to their original permeability, based on the standard microcapsule.

Example 6

Implantation

35 Approximately 0.5 ml of microcapsules were taken for each sample. The samples were washed 2 times in 10 ml

each of isotonic saline. After the final wash, each sample of microcapsules was suspended in 5 ml phosphate buffered saline (0.2M) pH 7.4 (PBS) and aliquoted into two equal parts. Duplicate animals, male swiss Sprague-Dawley mice 16-20 weeks old were used for each composition. Implants were made intraperitoneally (i.p.) using a 15 gauge needle. Animals were under ether anaesthesia. Microcapsules having an outermost layer of PLL without the grafted water soluble non-ionic polymers were used as controls.

Example 7

Characterization of Implanted Microcapsules

The implants were retrieved after one week using peritoneal lavage. 5ml of PBS, containing 10U/ml heparin, was injected with pressure using a 22 gauge needle. The microcapsules were recovered using a transfer pipette through a small hole made in the muscle flap over the peritoneal cavity.

a) Cell Counts

An immediate count of free cells recovered in the fluid in conjunction with the microcapsules was taken. These cells were incubated in polystyrene petri dishes for 2 hrs and then washed and fixed in 2% glutaraldehyde. Those cells adhering to the petri dish were nearly uniformly found to be macrophages as revealed using a monoclonal antibody and secondary fluorescence technique. The primary antibody was a rat anti-mouse macrophage antibody, clone #M1-70.15 from Sera-lab obtained from Accurate Chemicals. The secondary antibody was a fluorescein conjugated goat anti-rat IgG polyclonal antibody obtained from Accurate Chemical. After antibody treatment, the samples were viewed by fluorescence microscopy. Some of the directly recovered peritoneal lavage fluid and some control microcapsules which were covered with cells were also treated using the antibody.

fluorescence technique and were qualitatively judged to be about 50% macrophages.

The results, shown in Figure 4, show that the number of macrophages free floating in the peritoneal fluid was 5 decreased by use of the products of this invention. This figure shows cell counts from the samples. As can be seen from this figure, use of the technology described in this invention lowers the number of macrophages and other cells induced by the presence of microcapsules in the peritoneal 10 cavity. Evidence of some foreign body giant cell formation was seen in all samples that had cellular attachment. Varying levels of fluorescence was seen in some macrophages which might be an artifact of non-uniform staining or may reflect different levels of cellular 15 activation. A few cells which were not macrophages were also seen but their numbers were small.

The number of cells present in the peritoneal cavity was inversely correlated to the molecular weight of the grafted PEO.

20 b) Photomicrographs

Figures 5 through 9 show a number of photomicrographs of the recovered microcapsules. Photographs for each type of microcapsule were taken through a 40X phase contrast and a 400X Hoffman optics microscope. The lower 25 magnification was used to reflect a broad cross-section of the microcapsules and the higher magnification was used to examine the surface of the microcapsules and closely examine cell attachment.

The control microcapsules, shown in Figure 5, showed 30 heavy cellular overgrowth as expected. Figure 5a shows a number of microspheres darkened by overgrowth of cells. Figure 5b is a higher resolution version of figure 5a, showing individual cells on the surface.

Microcapsules made according to the invention 35 described herein showed little or no cell attachment. This can be seen by the clarity and transparency of the microcapsular surfaces at the 40X magnification.

25

Additionally, at 400X magnification, surfaces of the microcapsules made using trifyl chloride and chlorocarbonate technology show clean surfaces.

Claims

1. A method for producing bio-compatible microcapsules for transplantation into an animal, wherein interactions between the microcapsules and the animal are decreased.

2. The method of claim 1 wherein there is decreased adherence to the microcapsules of cells from the animal.

3. The method of claim 1 wherein there is decreased immune response by the animal to the microcapsules.

4. The method of claim 1 wherein there is decreased overgrowth of the microcapsules by cells from the animal.

5. A method for making microcapsules comprising using, as an outer layer, non-ionic water soluble polymers that are stable in a biological environment grafted to at least one of the layers of the microcapsule membrane made of polycationic polymers, wherein the grafting comprises the steps of:

a) activating the free reactive groups capable of being covalently linked to the coupling agent on the water soluble non-ionic polymers, and

b) coupling the activated water soluble non-ionic polymers to the polycationic polymers.

6. The method of claim 5 wherein the reactive groups are selected from the group consisting of hydroxyls, carboxyls, diols, aldehydes, amines, and thiols.

7. The method of claim 5 wherein the non-ionic water soluble polymers are selected from the group consisting of poly(ethylene oxide), poly(vinyl pyrrolidone), poly(ethyl oxazoline), poly(vinyl alcohol) and polysaccharides.

8. The method of claim 7 wherein the poly(ethylene oxide) is between 2000 and 50,000 daltons per molecule.

9. The method of claim 5 wherein the polycationic polymers are selected from the group consisting of polylysine, polyornithine, polyethyleneimine, polyallylamine, and mixed copolymers thereof.

10. The method of claim 9 wherein the polylysine is between 10,000 d and 75,000 d.

11. The method of claim 10 wherein the polylysine is approximately 17,500 d.

12. The method of claim 5 wherein activation is accomplished using an activation agent selected from the group consisting of carbodiimidazole, sulfonyl chlorides and chlorocarbonates.

13. The method of claim 12 wherein the sulfonyl chloride is trifyl chloride.

14. The method of claim 12 wherein the sulfonyl chloride is tresyl chloride.

15. The method of claim 12 wherein the sulfonyl chloride is tosyl chloride.

16. The method of claim 12 wherein the sulfonyl chloride is pentafluorobenzenesulfonyl chloride.

17. The method of claim 12 wherein the chlorocarbonate is p-nitrophenyl chlorocarbonate.

18. The method of claim 12 wherein the chlorocarbonate is 2,4,5 trichlorophenyl chlorocarbonate.

19. The method of claim 12 wherein the chlorocarbonate is N-hydroxysuccinamide chlorocarbonate.

20. A method for producing transplantable microcapsules wherein the surface is resistant to cellular attachment comprising forming an outer layer of non-ionic water soluble polymers which have been grafted to at least one of the layers, made of polycationic polymers, of the microcapsule membrane.

21. The method of claim 20 wherein the non-ionic water soluble polymers are selected from the group consisting of poly(ethylene oxide), poly(vinyl pyrrolidone), poly(ethyl oxazoline), poly(vinyl alcohol) and polysaccharides.

22. The method of claim 20 wherein the polycationic polymers are selected from the group consisting of polylysine, polyornithine, polyethyleneimine, polyallylamine, and mixed copolymers thereof.

23. The method of claim 20 wherein the polylysine is between 10,000 d and 75,000 d.

24. The method of claim 23 wherein the polylysine is approximately 17,500 d.

25. A method for producing transplantable microcapsules wherein a non-ionic water soluble layer surrounds the microcapsule comprising grafting water soluble non-ionic polymers to polycationic polypeptides and using said grafted material as a layer of the microcapsules.

26. A biocompatible microcapsule for transplantation into an animal comprising an outermost layer of non-ionic

water soluble polymers that have been grafted to at least one of the layers, made of polycationic polymers, of the microcapsule membrane.

27. The microcapsule of claim 26 wherein the non-ionic water soluble polymers are selected from the group consisting of poly(ethylene oxide)2, poly(vinyl pyrrolidone), poly(ethyl oxazoline), poly(vinyl alcohol) and polysaccharides.

28. The microcapsule of claim 27 wherein the poly(ethylene oxide) is between 2000 and 50,000 daltons per molecule.

29. The microcapsule of claim 27 wherein the polysaccharides are dextran.

30. The microcapsule of claim 27 wherein the polysaccharides are hyaluronic acid.

31. The microcapsule of claim 27 wherein the water soluble non-ionic polymers are branched or unbranched.

32. The microcapsule of claim 27 wherein the water soluble non-ionic polymers are unbranched.

33. The microcapsule of claim 26 wherein the polycationic polypeptides are selected from the group consisting of polylysine, polyornithine, polyethyleneimine, polyallylamine, and mixed copolymers thereof.

34. The microcapsule of claim 26 wherein the polylysine is between 10,000 d and 75,000 d.

35. The microcapsule of claim 34 wherein the polylysine is approximately 17,500 d.

36. A method for grafting water soluble non-ionic polymers to polycationic polymers comprising:

- a) activating the reactive groups capable of being covalently linked to a coupling agent on the water soluble non-ionic polymers by using an activation agent selected from the group consisting of carbodiimidazole, sulfonyl chlorides and chlorocarbonates, and
- b) coupling the activated water soluble non-ionic polymers to the polycationic polypeptides.

37. The method of claim 36 wherein the reactive groups are selected from the group consisting of hydroxyls, carboxyls, diols, aldehydes, amines, and thiols.

38. The method of claim 36 wherein the non-ionic water soluble polymers are selected from the group consisting of poly(ethylene oxide), poly(vinyl pyrrolidone), poly(ethyl oxazoline), poly(vinyl alcohol) and polysaccharides.

39. The method of claim 36 wherein the polycationic polymers are selected from the group consisting of polylysine, polyornithine, polyethyleneimine, polyallylamine, and mixed copolymers thereof.

40. The method of claim 36 wherein the sulfonyl chloride is trifyl chloride.

41. The method of claim 36 wherein the sulfonyl chloride is tresyl chloride.

42. The method of claim 36 wherein the sulfonyl chloride is tosyl chloride.

43. The method of claim 36 wherein the sulfonyl chloride is pentafluorobenzenesulfonyl chloride.

44. The method of claim 36 wherein the chlorocarbonate is p-nitrophenyl chlorocarbonate.

45. The method of claim 36 wherein the chlorocarbonate is 2,4,5 trichlorophenyl chlorocarbonate.

46. The method of claim 36 wherein the chlorocarbonate is N-hydroxysuccinamide chlorocarbonate.

1/12




FIG. 1.

2/12




FIG. 2.




FIG. 3.




FIG. 4.

SUBSTITUTE SHEET

4/12




FIG. 5A.

FIG. 5B.

5/12




FIG. 5C.

6/12




FIG. 6A.





FIG. 6B.

7/12



8/12




FIG. 7B.




FIG. 7A.

SUBSTITUTE SHEET

9/12




FIG. 8C.




FIG. 8B.



FIG. 8A.

10/12



FIG. 9E.




FIG. 9F.




FIG. 9C.




FIG. 9D.




FIG. 9A.




FIG. 9B.

11/12

FIG. 10C.




FIG. 10B.



FIG. 10A.



SUBSTITUTE SHEET

12/12




FIG. 11E.



FIG. 11F.




FIG. 11C.



FIG. 11D.




FIG. 11A.




FIG. 11B.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US91/07051

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹³

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC(5): A61K 9/14
 U.S. CL. 424/489

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴

Classification System ⁵	Classification Symbols
U.S.	424/489, 490, 493, 497
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁶	

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

Category ⁸	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
Y	US, A, 4,434,150 (AZAD) 28 February 1984 See entire document.	1-46
Y	US, A, 4,076,800 (MARSH) 28 February 1978 See entire document.	1-46

- * Special categories of cited documents: ¹⁵
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ⁹

05 December 1991

Date of Mailing of this International Search Report ¹⁰

21 JAN 1992

International Searching Authority ¹¹

ISA/US

Signature of Authorized Officer ¹²

Louis A. Piccone

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)